Epstein-Barr Virus (EBV): The Virus Inside Us All

Most people reading this carry a virus they rarely think about. The US Centers for Disease Control and Prevention (CDC) reports that about 9 in 10 adults have antibodies showing a current or past Epstein-Barr virus (EBV) infection. [1] The virus settles into immune cells for life, usually without symptoms, yet it is also tied to infectious mononucleosis, to several cancers, and, in a landmark 2022 study, to multiple sclerosis. This article explains how EBV gets in, how it hides, and what the evidence does and does not show.

Educational content, not medical advice. Talk to your doctor before changing any medication, treatment, or routine. Information here reflects published research, but every person's situation differs.

This piece goes deeper than the overview in how viruses work from infection to replication and expands on the short EBV section in the herpes virus family guide. For a parallel look at a different virus that lives inside immune cells, see the HIV deep dive.

EBV at a glance

Feature	What the evidence says
Formal name	Human herpesvirus 4 (HHV-4), a gammaherpesvirus
How common	About 9 in 10 adults carry antibodies, per the CDC [1]
Main route	Saliva; also blood, semen, transfusions, and organ transplants [1]
Typical first infection	Often silent in childhood; mono is most common in teens and young adults [1] [6]
Where it hides	Memory B cells, with most viral genes switched off
Linked cancers	Burkitt lymphoma, nasopharyngeal carcinoma, Hodgkin and non-Hodgkin lymphomas, post-transplant lymphoproliferative disorder, some gastric cancers [2]
Linked autoimmune disease	Multiple sclerosis [3]
Vaccine	None approved; an mRNA candidate has been in Phase 1/2 trials [8]

Discovery: found in cancer cells

EBV was the first human virus to be linked with cancer. In 1964 Anthony Epstein, Bert Achong, and Yvonne Barr reported virus particles in lymphoblasts cultured from Burkitt lymphoma, a fast-growing B-cell tumor, in a short paper in The Lancet. [4] The virus was named after two of those researchers.

The lymphoma itself had been described by the surgeon Denis Burkitt in African children, and its geography suggested an environmental cofactor, an early hint that the virus alone might not be enough. That insight still shapes the field. A virus carried by most adults cannot, by itself, explain a rare cancer.

EBV belongs to the gammaherpesvirus subfamily, which specializes in establishing long-term infection in lymphocytes. Its relative Kaposi sarcoma-associated herpesvirus (HHV-8) shares that lifestyle.

How EBV gets into a cell: two doors, two keys

EBV infects two main cell types, and it uses different entry routes for each. This matters because the two cell types play different roles. One is a factory, the other is a hiding place.

Entering B cells

B cells are the white blood cells that make antibodies. The viral surface protein gp350 binds to a B-cell surface receptor called CD21 (complement receptor 2), which normally helps B cells grab antigens coated with complement proteins. A second viral protein complex (gp42 with gH/gL) then engages HLA class II molecules, triggering the fusion of the viral envelope with the cell membrane and releasing the viral capsid into the cell.

Think of it as a two-step lock. The first key lets the virus dock at the door; the second one opens it.

Entering epithelial cells

Epithelial cells line the throat, salivary glands, and nasopharynx, and they lack CD21. In these cells, the gH/gL complex binds integrins (cell-surface adhesion proteins) instead, and gp350 plays a minor role. Epithelial cells are where the virus can make large numbers of new particles, which are then shed in saliva and passed to the next person. B cells, by contrast, are where it persists. This division of labor, one cell type for spread and one for staying, is part of why the virus is so successful.

The same entry proteins are the targets of vaccine design, which is why gp350 appears again in the vaccine section below.

The master strategy: lifelong latency in memory B cells

Inside a B cell, EBV does not need to destroy its host to survive. It pushes the infected cell down the normal path that B cells follow after meeting an antigen, ending in a long-lived memory B cell. In that cell, the viral genome sits as a small circular piece of DNA called an episome, which is copied along with the host's own chromosomes whenever the cell divides.

An analogy helps. Most viruses behave like burglars who break in, take what they want, and leave a mess. EBV behaves more like a sleeper agent who takes a job at the company. It uses the cell's own record-keeping system, immune memory, to carry its DNA through decades of cell division while drawing almost no attention.

In that quiet state, almost no viral proteins are made, so the immune system has little to detect. The infection is controlled, not cleared. That is why the answer to "can EBV be eliminated from the body?" is no, at least with current knowledge.

The four latency programs

EBV does not use all its genes in all cells. Researchers describe a small number of gene-expression patterns, called latency programs, each tied to a different cellular setting. The table is a simplification, because real tumors often show mixed or variant patterns.

Latency program	Viral genes active (simplified)	Where it is typically seen
Latency 0	Essentially none	Resting memory B cells in healthy carriers
Latency I	EBNA1	Burkitt lymphoma
Latency II	EBNA1, LMP1, LMP2A/B	Hodgkin lymphoma, nasopharyngeal carcinoma
Latency III	All EBNAs and LMPs	Cells in acute mono; post-transplant lymphoproliferative disease

Gastric cancer fits poorly into this scheme. A systematic review of EBV gene expression in gastric carcinomas found EBNA1 in about 98% of cases and LMP2A in about 54%, but LMP1 in only about 10%, a pattern closer to a restricted Latency I-like profile than to textbook Latency II. [5] The lesson is that the programs are useful labels, not rigid boxes.

Why does the pattern matter? Each viral protein has a different effect. EBNA1 lets the episome be copied with the cell, which is why almost every EBV-positive tumor expresses it. LMP1 mimics a growth-promoting receptor signal. The more of these signals a cell shows, the more it grows, and the more visible it becomes to T cells that patrol for infected cells.

Reactivation and spread

Latent virus can reactivate into the lytic cycle, in which the cell makes new viral particles. In healthy carriers, this happens intermittently and without symptoms, and the virus can be detected in saliva. That is what makes a person with no symptoms still a source of transmission.

The CDC lists saliva as the main route, for example through kissing or sharing drinks, food, utensils, or toothbrushes. The virus can also be spread by blood and semen during sex, blood transfusions, and organ transplants. [1] Hence the nickname "kissing disease" for mono.

Infectious mononucleosis: when timing matters

Early in life, a first EBV infection is often silent or looks like a mild childhood illness. When the first infection comes later, in adolescence or early adulthood, the immune response is more intense and can cause infectious mononucleosis ("mono"). A 2024 updated review puts the typical age range at 15 to 24 years. [6] The CDC lists fatigue, fever, sore throat, swollen neck lymph nodes, an enlarged spleen, a swollen liver, and rash among the symptoms. [1]

Much of what makes a person feel unwell is the immune reaction rather than the virus itself. A large wave of CD8 T cells (killer T cells) responds to infected B cells, and these show up on a blood smear as unusual-looking lymphocytes. Fatigue is the classic symptom. It generally resolves within about three months. [6]

What the numbers look like

Feature	Figure	Source
Splenomegaly (enlarged spleen)	About 50% of patients	2024 updated review [6]
Hepatomegaly (enlarged liver)	About 10%	2024 updated review [6]
Rash	10% to 45%	2024 updated review [6]
Spontaneous splenic rupture	0.1% to 0.5%	2024 updated review [6]
Typical advice on contact sports	Avoid for about 8 weeks	2024 updated review [6]
Sore-throat patients aged 16 to 20 who have mono	About 1 in 13	JAMA systematic review, 2016 [7]

A systematic review of published case reports of splenic rupture in mono found 85 cases, with a mean age of 22, 70% male, and abdominal pain in 88%; the mean time from symptom onset to rupture was 14 days. [9] Rupture is rare, but it is the reason clinicians raise the issue of contact sports.

Diagnosis and treatment

CDC notes that lab tests are usually not needed to diagnose mono, though specific tests may be used in atypical cases, and that antibody blood tests can distinguish a recent infection from a past one. [1] [2] A traditional bedside test looks for heterophile antibodies, which are antibodies that stick to red blood cells of other species, a by-product of the broad B-cell activation that EBV causes. In the JAMA review, atypical lymphocytes at or above 10% on a blood smear had a summary likelihood ratio of 11.4, and sore throat and fatigue were sensitive signs but not specific ones. [7]

There is no specific treatment. CDC describes care as fluids, rest, and over-the-counter medicine for pain and fever. [1] A 2012 review found few treatment studies and said that antivirals such as acyclovir might help in complicated cases but that data were scarce. [11] This article cannot advise on any individual illness; anyone with severe symptoms, abdominal pain, or breathing difficulty should seek medical care.

EBV and cancer

EBV is classified by the International Agency for Research on Cancer as a carcinogen to humans. It is a necessary but not sufficient partner in the cancers below. Most carriers never get any of them, because tumor formation also needs other changes, such as genetic mutations, a weakened immune response, or other infections. The general logic of how cells escape growth controls is covered in what causes cancer. The CDC clinical overview lists the main EBV-associated cancers as Burkitt lymphoma, nasopharyngeal carcinoma, Hodgkin and non-Hodgkin lymphoma, post-transplant lymphoproliferative disorder, leiomyosarcoma, and T-cell lymphomas. [2]

Cancer	EBV link	Key point
Burkitt lymphoma	57.5% EBV-positive worldwide; 86.8% in African studies	MYC gene rearrangement is the molecular hallmark [12] [13]
Hodgkin lymphoma	Varies by region and subtype	Poorer survival with EBV-positive disease in a 42-study meta-analysis [14]
Nasopharyngeal carcinoma	Strongly EBV-associated in high-incidence regions	Plasma EBV DNA used for screening in trials [15]
Post-transplant lymphoproliferative disorder	Common in immunosuppressed patients	Immunity falters, infected B cells grow
Gastric carcinoma	7.5% of conventional adenocarcinomas	Higher in men, diffuse-type, and proximal tumors [16]

Burkitt lymphoma

Burkitt lymphoma is defined by a rearrangement that puts the MYC gene (a growth-promoting gene) next to an immunoglobulin gene region, so that MYC is switched on at the wrong level. [12] The EBV link is strong but not universal. A 2023 meta-analysis of 135 studies (4,837 patients) found EBV in 57.5% of Burkitt lymphomas worldwide, with significant publication bias, and a 2026 meta-analysis of African studies found 86.8%. [13] [17] The wide gap probably reflects differences in geography and in the type of Burkitt lymphoma studied, though the meta-analyses do not settle the question.

The malaria cofactor story is more complicated than textbooks suggest. A 2021 meta-analysis found that malaria infection overall did not significantly raise the odds of endemic Burkitt lymphoma (odds ratio 0.87), while a high malaria antibody titer gave an odds ratio of 1.50 that sat on the border of statistical significance. [18] The hypothesis that chronic malaria drives B-cell activation remains plausible, but the epidemiological evidence is mixed.

Hodgkin lymphoma

In classical Hodgkin lymphoma, the giant Reed-Sternberg cells are the tumor cells, and when EBV is present they run the Latency II program. LMP1 sends survival signals that resemble those from the B-cell co-receptor CD40, which helps a cell with damaging mutations avoid cell death. The share of tumors that are EBV-positive varies widely by region, age, and subtype, and a 2022 meta-analysis of 42 studies and 9,570 patients found EBV positivity associated with poorer overall survival (hazard ratio 1.443) and disease-specific survival (hazard ratio 2.312). [14] That is an association in a pooled analysis, and it does not indicate what causes the worse outcome.

Nasopharyngeal carcinoma

Nasopharyngeal carcinoma (NPC) arises in the upper throat behind the nose. In high-incidence populations, it is strongly tied to EBV, and plasma EBV DNA has become a tool for early detection. In a 2017 New England Journal of Medicine study, researchers screened 20,174 people without symptoms. EBV DNA was found in 1,112 (5.5%) of them at first, and 309 still tested positive about four weeks later. [15] Thirty-four people were diagnosed with NPC, 71% of them at stage I or II compared with 20% in a historical group, and three-year progression-free survival was 97% versus 70%. [15] Sensitivity was 97.1% and specificity 98.6%. [15]

Those figures come from a study in a high-risk population, and screening benefit elsewhere cannot be assumed. A separate 2024 analysis of US data reported that intermediate- and high-incidence populations accounted for 10.7% of person-years but 42.7% of NPC cases, which is the sort of concentration that determines where serologic screening might be worthwhile. [19]

Post-transplant lymphoproliferative disorder

After an organ or stem-cell transplant, drugs suppress the T cells that normally hold EBV-infected B cells in check. The infected cells can then multiply. The condition ranges from mild expansions to aggressive lymphoma. Managing it often involves reducing immunosuppression when that is safe, which lets the patient's immune system regain control. It illustrates the central lesson of EBV: the immune system is the thing keeping the virus in a harmless state.

Gastric cancer

A 2023 meta-analysis of 220 studies covering more than 68,000 conventional gastric adenocarcinomas found EBV in 7.5% of tumors, with higher rates in men, in diffuse-type tumors, and in proximal tumors. [16] The authors estimated that an EBV vaccine could prevent about 81,000 EBV-associated gastric cancers a year worldwide, a figure that assumes the link is causal. [16] That is an estimate built on an assumption, not a measured result, and it should be read that way.

EBV and multiple sclerosis

Multiple sclerosis (MS) is an autoimmune disease in which the immune system attacks myelin, the insulation around nerve fibers. For years, epidemiologists suspected EBV because MS was rare among people who had never been infected. Suspicion was not proof, because most adults are infected, which makes it hard to separate cause from coincidence.

The 2022 military cohort

In 2022, Bjornevik and colleagues published a study in Science that followed more than 10 million young adults on active duty in the US military. Of these, 955 were diagnosed with MS during service. [3] The risk of MS rose about 32-fold after EBV infection, and it did not rise after infection with other viruses, including cytomegalovirus. [3] Levels of serum neurofilament light chain, a marker of nerve-cell damage, rose only after EBV seroconversion. [3]

The design is the strength. Stored blood samples were collected before MS appeared, so the researchers could tell which came first, infection or disease. The authors concluded that the data support a causal role for EBV in MS, and several 2023 reviews in Nature Reviews Microbiology, Nature Reviews Neurology, and The Lancet Neurology went on to examine the mechanisms and the prospects for prevention. [20]

That is strong evidence, but it comes with limits. A 32-fold relative increase applies to a rare outcome, and most people infected with EBV never develop MS. Genetics and other environmental factors also appear to matter, which the Frontiers in Immunology review of MS risk factors discusses alongside EBV.

How might a virus cause MS?

Several mechanisms are under study, and they may not exclude one another.

Molecular mimicry. Lanz and colleagues reported in Nature in 2022 that an antibody found in cerebrospinal fluid recognized both the EBV protein EBNA1 and a central nervous system protein called GlialCAM. [21] A chemical modification of GlialCAM helped the mimicry, and immunizing mice with EBNA1 worsened disease in an MS mouse model. [21] The idea is that an immune response aimed at the virus could, in some people, also hit a brain protein.

Failed immune control. A 2023 Cell paper reported that natural killer cells and EBV-specific T cells normally remove autoreactive GlialCAM-specific cells, and that EBV variants of HLA-E help those cells escape. [22] Certain genetic combinations were associated with up to a 260-fold higher MS risk in that analysis. [22]

Infected B cells in the brain. A 2025 PNAS study of brain tissue found EBNA1 and LMP1 enriched in MS lesions. [23] A 2024 PNAS study found that EBV-infected-B-cell-specific sequences made up about 13% of T-cell receptor reads in the cerebrospinal fluid of MS patients. [24]

None of these has been established as the single mechanism. The honest summary is that the epidemiological case is strong, and the biology is still being worked out.

Other EBV-related conditions

In rare people, primary infection does not resolve normally. Instead, T cells or NK cells become chronically infected, causing a severe syndrome called chronic active EBV disease. It is more often reported in East Asia, and it can progress to lymphoma. Because it is rare, the evidence base is limited and this article does not give figures for it.

The CDC clinical overview also lists a range of conditions that EBV can affect in some patients, including viral meningitis, encephalitis, optic neuritis, transverse myelitis, and Guillain-Barré syndrome, as well as pneumonia, pancreatitis, and myocarditis. [2] These are uncommon outcomes, and the clinical overview notes that people with weakened immune systems may have more severe symptoms and complications. [2]

Vaccine prospects

A vaccine that prevented primary EBV infection could, in principle, prevent mono and some cancers, and possibly MS. None of these effects has been proven. A 2018 review noted that no EBV vaccine was licensed. It described an earlier phase 2 trial of a recombinant gp350 vaccine, which reduced mononucleosis but not infection, and suggested that newer gp350 forms, such as nanoparticles, might work better. [8] [25] A 2015 Cell study found that gp350 displayed on self-assembling nanoparticles produced stronger neutralizing antibodies in mice and non-human primates. [26]

Moderna's mRNA-1189 is the best-known mRNA candidate. ClinicalTrials.gov lists it in trial NCT05164094, a Phase 1/2 randomized, observer-blind, placebo-controlled, dose-ranging study. It enrolled 867 participants aged 10 to 30, started December 28, 2021, and was listed as active, not recruiting. [27] The trial's design tests safety and immune response; it does not by itself show protection from disease. For background on how mRNA vaccines are built, see mRNA vaccines and the COVID-19 breakthrough, and for what vaccines do to immune memory, see how vaccines train memory B cells.

An unanswered design question remains. A vaccine could aim to block infection entirely, or it could aim to reduce the severity of a first infection and lower the number of infected B cells that persist. The two goals lead to different trials and different endpoints, and the NIH meeting reported in Science Translational Medicine in 2011 recommended that future trials target both mono and cancers using predictive surrogate markers. [28]

Common misconceptions

"EBV is rare." It is one of the most widespread human viruses; about 9 in 10 adults show evidence of infection. [1]

"Carrying EBV means I will get cancer or MS." The overwhelming majority of carriers do neither. Those outcomes need other contributing factors.

"Mono means a person is still contagious for months." The virus can be shed in saliva intermittently in healthy carriers, so ongoing shedding is normal and not a sign of continuing illness. How long a person should avoid close contact is a question for a clinician.

"The MS link is just a statistical association." The military cohort used samples taken before disease onset, which addresses the order of events, and mechanistic studies add support. Even so, researchers still debate how EBV contributes, and not every question is settled.

"An antiviral can cure latent EBV." No treatment removes the latent virus from memory B cells, and evidence for antivirals in mono itself is limited. [11]

What this means

EBV is a study in how a virus can succeed by being quiet. It rides inside memory B cells, copies itself along with the host genome, and shows up in saliva often enough to reach almost everyone. Most of the time, that is the whole story. The harm appears when timing, genetics, or immune control change: a first infection late in adolescence, a transplant, a genetic background that tilts the immune system, or a long chain of events that in a small minority leads to cancer or MS.

The practical lesson is about interpreting numbers. A 32-fold risk increase, a 7.5% share of gastric cancers, and a 57.5% share of Burkitt lymphomas each answer a different question, and none of them says what will happen to an individual carrier. The next decade of vaccine trials is likely to test whether blocking the first infection changes any of those outcomes.

Frequently asked questions

Q: Does everyone who gets EBV develop mono? A: No. A first infection in early childhood is often silent or mild. Mono is most common when the first infection happens in the teens or early adulthood, and a 2024 review gives a typical age range of 15 to 24 years.

Q: Can EBV be cleared from the body? A: No. After the first infection, the virus persists for life in memory B cells, where the immune system keeps it in check but does not eliminate it. Occasional reactivation usually passes without symptoms in healthy people.

Q: How is EBV transmitted? A: Mainly through saliva, for example by kissing or sharing drinks, food, utensils, or toothbrushes. It can also spread through blood and semen during sex, blood transfusions, and organ transplants, according to the CDC.

Q: Does EBV cause cancer in most infected people? A: No. Most carriers never develop an EBV-associated cancer. Tumors need additional factors such as genetic changes, immune suppression, or other infections, and the share of each cancer type that is EBV-positive varies, for example 7.5% of conventional gastric adenocarcinomas.

Q: What is the connection between EBV and multiple sclerosis? A: A 2022 study in Science followed more than 10 million US military personnel, 955 of whom developed MS. MS risk rose about 32-fold after EBV infection but not after other viruses. Mechanisms such as molecular mimicry with GlialCAM are being studied.

Q: Is there treatment for EBV-associated cancers? A: Treatment depends on the cancer type and stage and is decided by oncology teams. This article does not give treatment advice. Reducing immunosuppression is one approach for post-transplant lymphoproliferative disorder when it is safe to do so.

Q: When might an EBV vaccine be available? A: No EBV vaccine is approved. Moderna's mRNA-1189 was in a Phase 1/2 trial of 867 participants aged 10 to 30, listed as active, not recruiting, so protection from disease has not been shown, and no approval date can be predicted.

Sources

1. CDC, "About Epstein-Barr virus" (accessed October 2026): https://www.cdc.gov/epstein-barr/about/index.html
2. CDC, "Clinical overview of EBV": https://www.cdc.gov/epstein-barr/hcp/clinical-overview/index.html
3. Bjornevik K, et al. (2022). Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. https://doi.org/10.1126/science.abj8222
4. Epstein MA, Achong BG, Barr YM (1964). Virus particles in cultured lymphoblasts from Burkitt's lymphoma. The Lancet 1(7335):702-703. https://doi.org/10.1016/S0140-6736(64)91524-7
5. Ribeiro J, et al. (2017). Epstein-Barr virus gene expression and latency pattern in gastric carcinomas: a systematic review. Future Oncology. https://doi.org/10.2217/fon-2016-0475
6. Infectious mononucleosis: an updated review (2024). Current Pediatric Reviews. https://doi.org/10.2174/1573396320666230801091558
7. Does this patient have infectious mononucleosis? The Rational Clinical Examination systematic review (2016). JAMA. https://doi.org/10.1001/jama.2016.2111
8. Vaccine development for Epstein-Barr virus (2018). Advances in Experimental Medicine and Biology 1045:477-493. https://doi.org/10.1007/978-981-10-7230-7_22
9. Splenic rupture in infectious mononucleosis: a systematic review of published case reports (2016). Injury. https://doi.org/10.1016/j.injury.2015.10.071
10. Current diagnosis and management of infectious mononucleosis (2012). Current Opinion in Hematology. https://doi.org/10.1097/moh.0b013e32834daa08
11. Solares et al. (2024). The functional interaction between Epstein-Barr virus and MYC in the pathogenesis of Burkitt lymphoma. Cancers. https://doi.org/10.3390/cancers16244212
12. Al-Khreisat et al. (2023). Worldwide prevalence of Epstein-Barr virus in patients with Burkitt lymphoma: a systematic review and meta-analysis. Diagnostics. https://doi.org/10.3390/diagnostics13122068
13. The prognostic value of EBV infection in Hodgkin lymphoma: a systematic review and meta-analysis (2022). Frontiers in Oncology. https://doi.org/10.3389/fonc.2022.1034398
14. Chan KCA, et al. (2017). Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. New England Journal of Medicine 377(6):513-522. https://doi.org/10.1056/NEJMoa1701717
15. Estimating the global burden of Epstein-Barr virus-associated gastric cancer: a systematic review and meta-analysis (2023). Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2022.07.042
16. Sebsibe et al. (2026). Burden of Epstein-Barr virus in gastric cancer, nasopharyngeal carcinoma, and Burkitt lymphoma in Africa. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-13980-6
17. Kotepui M, Kotepui KU (2021). Malaria infection and risk for endemic Burkitt lymphoma: a systematic review and meta-analysis. International Journal of Environmental Research and Public Health. https://doi.org/10.3390/ijerph18115886
18. Identification of high-incidence populations in the United States for anti-EBV serologic screening for nasopharyngeal carcinoma (2024). Cancer Epidemiology, Biomarkers & Prevention. https://doi.org/10.1158/1055-9965.epi-24-0576
19. Epstein-Barr virus and multiple sclerosis (2023). Nature Reviews Microbiology. https://doi.org/10.1038/s41579-022-00770-5
20. Lanz TV, et al. (2022). Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature. https://doi.org/10.1038/s41586-022-04432-7
21. Ineffective control of Epstein-Barr-virus-induced autoimmunity increases the risk for multiple sclerosis (2023). Cell. https://doi.org/10.1016/j.cell.2023.11.015
22. Epstein-Barr virus and the immune microenvironment in multiple sclerosis: insights from high-dimensional brain tissue imaging (2025). PNAS. https://doi.org/10.1073/pnas.2425670122
23. Expanded T lymphocytes in the cerebrospinal fluid of multiple sclerosis patients are specific for Epstein-Barr-virus-infected B cells (2024). PNAS. https://doi.org/10.1073/pnas.2315857121
24. Sokal EM, et al. (2007). Randomized trial of a recombinant gp350 vaccine. Journal of Infectious Diseases. https://doi.org/10.1086/523813
25. Kanekiyo M, et al. (2015). gp350 displayed on self-assembling nanoparticles. Cell. https://doi.org/10.1016/j.cell.2015.07.043
26. ClinicalTrials.gov, NCT05164094, mRNA-1189 Phase 1/2 study: https://clinicaltrials.gov/study/NCT05164094
27. Cohen JI, Fauci AS, Varmus H, Nabel GJ (2011). Epstein-Barr virus: an important vaccine target for cancer prevention. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.3002878
28. Risk factors for multiple sclerosis in the context of Epstein-Barr virus infection (2023). Frontiers in Immunology. https://doi.org/10.3389/fimmu.2023.1212676

---

Read next:

• Cytomegalovirus (CMV): A Complete Deep Dive
• Shingles & Varicella-Zoster Virus: Deep Dive
• BK Virus, JC Virus & Polyomaviruses Explained